Approval marks Venus Remedies’ entry into Argentina for Ceftriaxone, taking total global
MAs for the antibiotic to 39

 Argentina is the 4th-largest pharmaceutical market in Latin America, valued at
approximately US$7.3 billion in 2023
 Approval strengthens Venus Remedies’ growing international anti infective portfolio amid
rising burden of infectious diseases in LATAM

Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), among
the world’s leading fixed dosage injectable manufacturers, has secured marketing authorization
from Argentina’s national regulatory authority for its antibiotic, Ceftriaxone. The approval marks
a significant milestone in the company’s expansion across Latin America, strengthening its
growing international portfolio and taking the total marketing authorizations (MAs) for
Ceftriaxone to 39 globally. The development further reinforces Venus Remedies’ commitment to
improving access to essential anti infective therapies while supporting India’s growing role as a
reliable supplier of high quality injectable pharmaceuticals worldwide.

Saransh Chaudhary, President, Global Critical Care, Venus Remedies Limited, and CEO,
Venus Medicine Research Centre, said, “The approval of Ceftriaxone in Argentina represents
an important step in strengthening our presence in the Latin American region. Argentina is the
fourth largest pharmaceutical market in Latin America, valued at approximately USD7.3 billion in
2023, making it a strategically important market for high quality critical care therapies.

Ceftriaxone remains a cornerstone antibiotic in the management of several serious bacterial
infections, including meningitis, respiratory tract infections, bloodstream infections, and surgical
infections, making it a critical therapy in hospital and intensive care settings. This authorization
aligns with our focus on delivering clinically relevant and widely accessible anti-infective
therapies across global markets.”

The broader Latin American pharmaceutical market continues to demonstrate steady growth,
reinforcing the region’s significance for India’s pharmaceutical exports and long-term healthcare
partnerships. The overall Latin American pharmaceutical market is estimated at nearly
US$91.85 billion in 2024, projected to reach US$ 172.71 billion by 2034, showing a healthy
CAGR of 6.52% across the forecast years.

Aditi K. Chaudhary, President, International Business, Venus Remedies Limited, said, “Securing
this marketing authorization in Argentina is a strategically important milestone in our Latin
America expansion journey. India exported approximately US$17.5 million worth of
pharmaceutical products to Argentina in 2024, while Latin America and the Caribbean
accounted for 6.69% of India’s total pharma exports in FY 2024–25. At Venus Remedies, we
remain focused on strengthening our presence in such high potential markets while supporting
the broader agenda of improving access to affordable and quality healthcare solutions globally.”

The approval enables Venus Remedies to commercialize Ceftriaxone in Argentina through its
established distribution networks, further strengthening its position in hospital driven critical care
injectable markets.

The development also reflects the company’s expanding international footprint across Latin
America and reinforces India’s growing reputation as a dependable supplier of high quality
pharmaceutical solutions. Venus Remedies remains committed to regulatory excellence,
sustainable growth, and improving access to life saving therapies for healthcare providers and
patients across global markets.